CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer By Ogkologos - August 14, 2025 376 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR The director’s cut: How Dr Catherine Elliott sees the future of... November 2, 2021 One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories... July 16, 2020 Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers November 15, 2023 Ovarian cancer screening trial did not save lives May 12, 2021 Load more HOT NEWS Identification of Actionable Molecular Alterations in NCI-MATCH ΤΙ ΕΙΝΑΙ EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the... COVID-19 Pandemic Halts Cancer Care and Damages Oncologists’ Wellbeing [ESMO Press...
